Abivax S.A. (ABVX)

Published 2026-03-23 • by yetanothervalueblog

BiotechnologyBiotechUlcerative ColitisInflammatoryPhase 3
Original Post ↗SEC:
[All][10-K][10-Q]
Market Intel:
Yahoo Finance 📊TradingView 📈Koyfin 🎯

Thesis Summary

Abivax ($ABVX) represents an undervalued biotech bet on its lead Phase 3 drug obefazimod for ulcerative colitis, offering high upside if trials succeed.

Quantitative Overlay

Detailed Deep Dive

Abivax ($ABVX) is a late-stage clinical biotechnology company developing obefazimod for chronic inflammatory diseases, particularly ulcerative colitis. The thesis highlights obefazimod's novel mechanism of action, promising Phase 2 efficacy/safety profile, and the market's underestimation of its Phase 3 success probability relative to its peers.